PMC:7205724 / 19472-20478 JSONTXT

{"project":"LitCovid-PubTator","denotations":[{"id":"665","span":{"begin":321,"end":330},"obj":"Species"},{"id":"679","span":{"begin":473,"end":477},"obj":"Gene"},{"id":"680","span":{"begin":371,"end":380},"obj":"Species"},{"id":"681","span":{"begin":506,"end":515},"obj":"Species"},{"id":"682","span":{"begin":584,"end":592},"obj":"Species"},{"id":"683","span":{"begin":666,"end":675},"obj":"Species"},{"id":"684","span":{"begin":734,"end":742},"obj":"Species"},{"id":"685","span":{"begin":843,"end":852},"obj":"Species"},{"id":"686","span":{"begin":857,"end":865},"obj":"Species"},{"id":"687","span":{"begin":360,"end":369},"obj":"Disease"},{"id":"688","span":{"begin":516,"end":525},"obj":"Disease"},{"id":"689","span":{"begin":714,"end":723},"obj":"Disease"},{"id":"690","span":{"begin":804,"end":813},"obj":"Disease"},{"id":"691","span":{"begin":449,"end":451},"obj":"CellLine"}],"attributes":[{"id":"A665","pred":"tao:has_database_id","subj":"665","obj":"Tax:2697049"},{"id":"A679","pred":"tao:has_database_id","subj":"679","obj":"Gene:103231639"},{"id":"A680","pred":"tao:has_database_id","subj":"680","obj":"Tax:2697049"},{"id":"A681","pred":"tao:has_database_id","subj":"681","obj":"Tax:2697049"},{"id":"A682","pred":"tao:has_database_id","subj":"682","obj":"Tax:694009"},{"id":"A683","pred":"tao:has_database_id","subj":"683","obj":"Tax:2697049"},{"id":"A684","pred":"tao:has_database_id","subj":"684","obj":"Tax:694009"},{"id":"A685","pred":"tao:has_database_id","subj":"685","obj":"Tax:2697049"},{"id":"A686","pred":"tao:has_database_id","subj":"686","obj":"Tax:694009"},{"id":"A687","pred":"tao:has_database_id","subj":"687","obj":"MESH:D007239"},{"id":"A688","pred":"tao:has_database_id","subj":"688","obj":"MESH:D007239"},{"id":"A689","pred":"tao:has_database_id","subj":"689","obj":"MESH:D007239"},{"id":"A690","pred":"tao:has_database_id","subj":"690","obj":"MESH:D007239"},{"id":"A691","pred":"tao:has_database_id","subj":"691","obj":"CVCL:4582"}],"namespaces":[{"prefix":"Tax","uri":"https://www.ncbi.nlm.nih.gov/taxonomy/"},{"prefix":"MESH","uri":"https://id.nlm.nih.gov/mesh/"},{"prefix":"Gene","uri":"https://www.ncbi.nlm.nih.gov/gene/"},{"prefix":"CVCL","uri":"https://web.expasy.org/cellosaurus/CVCL_"}],"text":"5 Recombinant type I IFN\n\n5.1 Hypothesis: IFNs play a role in anti-viral immunity\nType I IFNs play a primary role in the inhibition of viral replication through the coordination of anti-viral immune responses and modulation of inflammatory responses [24].\n\n5.2 Rational: Recombinant type I IFN can effectively inhibit SARS-CoV2 replication\nIn 24–48 h after infection, SARS-CoV2 replication reaches titer that causes the cytopathic effect in Vero E6 cells, which express ACE2 and thus are susceptible to SARS-CoV2 infection [25]. It is similar to the viral replication kinetics for SARS-CoV [25]. Pretreatment with recombinant type I IFN could effectively inhibit SARS-CoV2 replication at both 24 and 48 h after infection [25]. For SARS-CoV, such an effect was present at 24 h but absent at 48 h after infection [25]. The difference between SARS-CoV2 and SARS-CoV in response to type I IFN treatment may be due to differences in structural proteins of these viruses, including NSP3, ORF3b, and ORF6 [25]."}

{"project":"LitCovid-PD-FMA-UBERON","denotations":[{"id":"T147","span":{"begin":452,"end":457},"obj":"Body_part"},{"id":"T148","span":{"begin":942,"end":950},"obj":"Body_part"}],"attributes":[{"id":"A147","pred":"fma_id","subj":"T147","obj":"http://purl.org/sig/ont/fma/fma68646"},{"id":"A148","pred":"fma_id","subj":"T148","obj":"http://purl.org/sig/ont/fma/fma67257"}],"text":"5 Recombinant type I IFN\n\n5.1 Hypothesis: IFNs play a role in anti-viral immunity\nType I IFNs play a primary role in the inhibition of viral replication through the coordination of anti-viral immune responses and modulation of inflammatory responses [24].\n\n5.2 Rational: Recombinant type I IFN can effectively inhibit SARS-CoV2 replication\nIn 24–48 h after infection, SARS-CoV2 replication reaches titer that causes the cytopathic effect in Vero E6 cells, which express ACE2 and thus are susceptible to SARS-CoV2 infection [25]. It is similar to the viral replication kinetics for SARS-CoV [25]. Pretreatment with recombinant type I IFN could effectively inhibit SARS-CoV2 replication at both 24 and 48 h after infection [25]. For SARS-CoV, such an effect was present at 24 h but absent at 48 h after infection [25]. The difference between SARS-CoV2 and SARS-CoV in response to type I IFN treatment may be due to differences in structural proteins of these viruses, including NSP3, ORF3b, and ORF6 [25]."}

{"project":"LitCovid-PD-MONDO","denotations":[{"id":"T139","span":{"begin":321,"end":325},"obj":"Disease"},{"id":"T140","span":{"begin":360,"end":369},"obj":"Disease"},{"id":"T141","span":{"begin":371,"end":375},"obj":"Disease"},{"id":"T142","span":{"begin":506,"end":510},"obj":"Disease"},{"id":"T143","span":{"begin":516,"end":525},"obj":"Disease"},{"id":"T144","span":{"begin":584,"end":592},"obj":"Disease"},{"id":"T145","span":{"begin":666,"end":670},"obj":"Disease"},{"id":"T146","span":{"begin":714,"end":723},"obj":"Disease"},{"id":"T147","span":{"begin":734,"end":742},"obj":"Disease"},{"id":"T148","span":{"begin":804,"end":813},"obj":"Disease"},{"id":"T149","span":{"begin":843,"end":847},"obj":"Disease"},{"id":"T150","span":{"begin":857,"end":865},"obj":"Disease"}],"attributes":[{"id":"A139","pred":"mondo_id","subj":"T139","obj":"http://purl.obolibrary.org/obo/MONDO_0005091"},{"id":"A140","pred":"mondo_id","subj":"T140","obj":"http://purl.obolibrary.org/obo/MONDO_0005550"},{"id":"A141","pred":"mondo_id","subj":"T141","obj":"http://purl.obolibrary.org/obo/MONDO_0005091"},{"id":"A142","pred":"mondo_id","subj":"T142","obj":"http://purl.obolibrary.org/obo/MONDO_0005091"},{"id":"A143","pred":"mondo_id","subj":"T143","obj":"http://purl.obolibrary.org/obo/MONDO_0005550"},{"id":"A144","pred":"mondo_id","subj":"T144","obj":"http://purl.obolibrary.org/obo/MONDO_0005091"},{"id":"A145","pred":"mondo_id","subj":"T145","obj":"http://purl.obolibrary.org/obo/MONDO_0005091"},{"id":"A146","pred":"mondo_id","subj":"T146","obj":"http://purl.obolibrary.org/obo/MONDO_0005550"},{"id":"A147","pred":"mondo_id","subj":"T147","obj":"http://purl.obolibrary.org/obo/MONDO_0005091"},{"id":"A148","pred":"mondo_id","subj":"T148","obj":"http://purl.obolibrary.org/obo/MONDO_0005550"},{"id":"A149","pred":"mondo_id","subj":"T149","obj":"http://purl.obolibrary.org/obo/MONDO_0005091"},{"id":"A150","pred":"mondo_id","subj":"T150","obj":"http://purl.obolibrary.org/obo/MONDO_0005091"}],"text":"5 Recombinant type I IFN\n\n5.1 Hypothesis: IFNs play a role in anti-viral immunity\nType I IFNs play a primary role in the inhibition of viral replication through the coordination of anti-viral immune responses and modulation of inflammatory responses [24].\n\n5.2 Rational: Recombinant type I IFN can effectively inhibit SARS-CoV2 replication\nIn 24–48 h after infection, SARS-CoV2 replication reaches titer that causes the cytopathic effect in Vero E6 cells, which express ACE2 and thus are susceptible to SARS-CoV2 infection [25]. It is similar to the viral replication kinetics for SARS-CoV [25]. Pretreatment with recombinant type I IFN could effectively inhibit SARS-CoV2 replication at both 24 and 48 h after infection [25]. For SARS-CoV, such an effect was present at 24 h but absent at 48 h after infection [25]. The difference between SARS-CoV2 and SARS-CoV in response to type I IFN treatment may be due to differences in structural proteins of these viruses, including NSP3, ORF3b, and ORF6 [25]."}

{"project":"LitCovid-PD-CLO","denotations":[{"id":"T231","span":{"begin":54,"end":55},"obj":"http://purl.obolibrary.org/obo/CLO_0001020"},{"id":"T232","span":{"begin":101,"end":102},"obj":"http://purl.obolibrary.org/obo/CLO_0001020"},{"id":"T233","span":{"begin":349,"end":351},"obj":"http://purl.obolibrary.org/obo/CLO_0001382"},{"id":"T234","span":{"begin":444,"end":457},"obj":"http://purl.obolibrary.org/obo/CLO_0051719"},{"id":"T235","span":{"begin":703,"end":705},"obj":"http://purl.obolibrary.org/obo/CLO_0001382"},{"id":"T236","span":{"begin":793,"end":795},"obj":"http://purl.obolibrary.org/obo/CLO_0001382"},{"id":"T237","span":{"begin":960,"end":967},"obj":"http://purl.obolibrary.org/obo/NCBITaxon_10239"}],"text":"5 Recombinant type I IFN\n\n5.1 Hypothesis: IFNs play a role in anti-viral immunity\nType I IFNs play a primary role in the inhibition of viral replication through the coordination of anti-viral immune responses and modulation of inflammatory responses [24].\n\n5.2 Rational: Recombinant type I IFN can effectively inhibit SARS-CoV2 replication\nIn 24–48 h after infection, SARS-CoV2 replication reaches titer that causes the cytopathic effect in Vero E6 cells, which express ACE2 and thus are susceptible to SARS-CoV2 infection [25]. It is similar to the viral replication kinetics for SARS-CoV [25]. Pretreatment with recombinant type I IFN could effectively inhibit SARS-CoV2 replication at both 24 and 48 h after infection [25]. For SARS-CoV, such an effect was present at 24 h but absent at 48 h after infection [25]. The difference between SARS-CoV2 and SARS-CoV in response to type I IFN treatment may be due to differences in structural proteins of these viruses, including NSP3, ORF3b, and ORF6 [25]."}

{"project":"LitCovid-PD-CHEBI","denotations":[{"id":"T166","span":{"begin":942,"end":950},"obj":"Chemical"}],"attributes":[{"id":"A166","pred":"chebi_id","subj":"T166","obj":"http://purl.obolibrary.org/obo/CHEBI_36080"}],"text":"5 Recombinant type I IFN\n\n5.1 Hypothesis: IFNs play a role in anti-viral immunity\nType I IFNs play a primary role in the inhibition of viral replication through the coordination of anti-viral immune responses and modulation of inflammatory responses [24].\n\n5.2 Rational: Recombinant type I IFN can effectively inhibit SARS-CoV2 replication\nIn 24–48 h after infection, SARS-CoV2 replication reaches titer that causes the cytopathic effect in Vero E6 cells, which express ACE2 and thus are susceptible to SARS-CoV2 infection [25]. It is similar to the viral replication kinetics for SARS-CoV [25]. Pretreatment with recombinant type I IFN could effectively inhibit SARS-CoV2 replication at both 24 and 48 h after infection [25]. For SARS-CoV, such an effect was present at 24 h but absent at 48 h after infection [25]. The difference between SARS-CoV2 and SARS-CoV in response to type I IFN treatment may be due to differences in structural proteins of these viruses, including NSP3, ORF3b, and ORF6 [25]."}

{"project":"LitCovid-sample-PD-IDO","denotations":[{"id":"T82","span":{"begin":143,"end":154},"obj":"http://purl.obolibrary.org/obo/IDO_0000608"},{"id":"T83","span":{"begin":194,"end":210},"obj":"http://purl.obolibrary.org/obo/GO_0006955"},{"id":"T84","span":{"begin":331,"end":342},"obj":"http://purl.obolibrary.org/obo/IDO_0000608"},{"id":"T85","span":{"begin":360,"end":369},"obj":"http://purl.obolibrary.org/obo/IDO_0000586"},{"id":"T86","span":{"begin":381,"end":392},"obj":"http://purl.obolibrary.org/obo/IDO_0000608"},{"id":"T87","span":{"begin":452,"end":457},"obj":"http://purl.obolibrary.org/obo/CL_0000000"},{"id":"T88","span":{"begin":491,"end":502},"obj":"http://purl.obolibrary.org/obo/IDO_0000467"},{"id":"T89","span":{"begin":516,"end":525},"obj":"http://purl.obolibrary.org/obo/IDO_0000586"},{"id":"T90","span":{"begin":559,"end":570},"obj":"http://purl.obolibrary.org/obo/IDO_0000608"},{"id":"T91","span":{"begin":676,"end":687},"obj":"http://purl.obolibrary.org/obo/IDO_0000608"},{"id":"T92","span":{"begin":714,"end":723},"obj":"http://purl.obolibrary.org/obo/IDO_0000586"},{"id":"T93","span":{"begin":804,"end":813},"obj":"http://purl.obolibrary.org/obo/IDO_0000586"},{"id":"T94","span":{"begin":960,"end":967},"obj":"http://purl.obolibrary.org/obo/NCBITaxon_10239"}],"text":"5 Recombinant type I IFN\n\n5.1 Hypothesis: IFNs play a role in anti-viral immunity\nType I IFNs play a primary role in the inhibition of viral replication through the coordination of anti-viral immune responses and modulation of inflammatory responses [24].\n\n5.2 Rational: Recombinant type I IFN can effectively inhibit SARS-CoV2 replication\nIn 24–48 h after infection, SARS-CoV2 replication reaches titer that causes the cytopathic effect in Vero E6 cells, which express ACE2 and thus are susceptible to SARS-CoV2 infection [25]. It is similar to the viral replication kinetics for SARS-CoV [25]. Pretreatment with recombinant type I IFN could effectively inhibit SARS-CoV2 replication at both 24 and 48 h after infection [25]. For SARS-CoV, such an effect was present at 24 h but absent at 48 h after infection [25]. The difference between SARS-CoV2 and SARS-CoV in response to type I IFN treatment may be due to differences in structural proteins of these viruses, including NSP3, ORF3b, and ORF6 [25]."}

{"project":"LitCovid-sample-CHEBI","denotations":[{"id":"T108","span":{"begin":942,"end":950},"obj":"Chemical"}],"attributes":[{"id":"A108","pred":"chebi_id","subj":"T108","obj":"http://purl.obolibrary.org/obo/CHEBI_36080"}],"text":"5 Recombinant type I IFN\n\n5.1 Hypothesis: IFNs play a role in anti-viral immunity\nType I IFNs play a primary role in the inhibition of viral replication through the coordination of anti-viral immune responses and modulation of inflammatory responses [24].\n\n5.2 Rational: Recombinant type I IFN can effectively inhibit SARS-CoV2 replication\nIn 24–48 h after infection, SARS-CoV2 replication reaches titer that causes the cytopathic effect in Vero E6 cells, which express ACE2 and thus are susceptible to SARS-CoV2 infection [25]. It is similar to the viral replication kinetics for SARS-CoV [25]. Pretreatment with recombinant type I IFN could effectively inhibit SARS-CoV2 replication at both 24 and 48 h after infection [25]. For SARS-CoV, such an effect was present at 24 h but absent at 48 h after infection [25]. The difference between SARS-CoV2 and SARS-CoV in response to type I IFN treatment may be due to differences in structural proteins of these viruses, including NSP3, ORF3b, and ORF6 [25]."}

{"project":"LitCovid-sample-PD-NCBITaxon","denotations":[{"id":"T186","span":{"begin":321,"end":330},"obj":"Species"},{"id":"T187","span":{"begin":371,"end":380},"obj":"Species"},{"id":"T188","span":{"begin":506,"end":515},"obj":"Species"},{"id":"T189","span":{"begin":584,"end":592},"obj":"Species"},{"id":"T190","span":{"begin":666,"end":675},"obj":"Species"},{"id":"T191","span":{"begin":734,"end":742},"obj":"Species"},{"id":"T192","span":{"begin":843,"end":852},"obj":"Species"},{"id":"T193","span":{"begin":857,"end":865},"obj":"Species"},{"id":"T194","span":{"begin":960,"end":967},"obj":"Species"}],"attributes":[{"id":"A191","pred":"ncbi_taxonomy_id","subj":"T191","obj":"NCBItxid:694009"},{"id":"A187","pred":"ncbi_taxonomy_id","subj":"T187","obj":"NCBItxid:2697049"},{"id":"A188","pred":"ncbi_taxonomy_id","subj":"T188","obj":"NCBItxid:2697049"},{"id":"A192","pred":"ncbi_taxonomy_id","subj":"T192","obj":"NCBItxid:2697049"},{"id":"A193","pred":"ncbi_taxonomy_id","subj":"T193","obj":"NCBItxid:694009"},{"id":"A194","pred":"ncbi_taxonomy_id","subj":"T194","obj":"NCBItxid:10239"},{"id":"A189","pred":"ncbi_taxonomy_id","subj":"T189","obj":"NCBItxid:694009"},{"id":"A186","pred":"ncbi_taxonomy_id","subj":"T186","obj":"NCBItxid:2697049"},{"id":"A190","pred":"ncbi_taxonomy_id","subj":"T190","obj":"NCBItxid:2697049"}],"namespaces":[{"prefix":"NCBItxid","uri":"http://purl.bioontology.org/ontology/NCBITAXON/"}],"text":"5 Recombinant type I IFN\n\n5.1 Hypothesis: IFNs play a role in anti-viral immunity\nType I IFNs play a primary role in the inhibition of viral replication through the coordination of anti-viral immune responses and modulation of inflammatory responses [24].\n\n5.2 Rational: Recombinant type I IFN can effectively inhibit SARS-CoV2 replication\nIn 24–48 h after infection, SARS-CoV2 replication reaches titer that causes the cytopathic effect in Vero E6 cells, which express ACE2 and thus are susceptible to SARS-CoV2 infection [25]. It is similar to the viral replication kinetics for SARS-CoV [25]. Pretreatment with recombinant type I IFN could effectively inhibit SARS-CoV2 replication at both 24 and 48 h after infection [25]. For SARS-CoV, such an effect was present at 24 h but absent at 48 h after infection [25]. The difference between SARS-CoV2 and SARS-CoV in response to type I IFN treatment may be due to differences in structural proteins of these viruses, including NSP3, ORF3b, and ORF6 [25]."}

{"project":"LitCovid-sample-sentences","denotations":[{"id":"T154","span":{"begin":0,"end":25},"obj":"Sentence"},{"id":"T155","span":{"begin":27,"end":83},"obj":"Sentence"},{"id":"T156","span":{"begin":84,"end":257},"obj":"Sentence"},{"id":"T157","span":{"begin":259,"end":273},"obj":"Sentence"},{"id":"T158","span":{"begin":274,"end":342},"obj":"Sentence"},{"id":"T159","span":{"begin":343,"end":531},"obj":"Sentence"},{"id":"T160","span":{"begin":532,"end":598},"obj":"Sentence"},{"id":"T161","span":{"begin":599,"end":729},"obj":"Sentence"},{"id":"T162","span":{"begin":730,"end":819},"obj":"Sentence"},{"id":"T163","span":{"begin":820,"end":1006},"obj":"Sentence"}],"namespaces":[{"prefix":"_base","uri":"http://pubannotation.org/ontology/tao.owl#"}],"text":"5 Recombinant type I IFN\n\n5.1 Hypothesis: IFNs play a role in anti-viral immunity\nType I IFNs play a primary role in the inhibition of viral replication through the coordination of anti-viral immune responses and modulation of inflammatory responses [24].\n\n5.2 Rational: Recombinant type I IFN can effectively inhibit SARS-CoV2 replication\nIn 24–48 h after infection, SARS-CoV2 replication reaches titer that causes the cytopathic effect in Vero E6 cells, which express ACE2 and thus are susceptible to SARS-CoV2 infection [25]. It is similar to the viral replication kinetics for SARS-CoV [25]. Pretreatment with recombinant type I IFN could effectively inhibit SARS-CoV2 replication at both 24 and 48 h after infection [25]. For SARS-CoV, such an effect was present at 24 h but absent at 48 h after infection [25]. The difference between SARS-CoV2 and SARS-CoV in response to type I IFN treatment may be due to differences in structural proteins of these viruses, including NSP3, ORF3b, and ORF6 [25]."}

{"project":"LitCovid-sample-Pubtator","denotations":[{"id":"665","span":{"begin":321,"end":330},"obj":"Species"},{"id":"687","span":{"begin":360,"end":369},"obj":"Disease"},{"id":"680","span":{"begin":371,"end":380},"obj":"Species"},{"id":"691","span":{"begin":449,"end":451},"obj":"CellLine"},{"id":"679","span":{"begin":473,"end":477},"obj":"Gene"},{"id":"681","span":{"begin":506,"end":515},"obj":"Species"},{"id":"688","span":{"begin":516,"end":525},"obj":"Disease"},{"id":"682","span":{"begin":584,"end":592},"obj":"Species"},{"id":"683","span":{"begin":666,"end":675},"obj":"Species"},{"id":"689","span":{"begin":714,"end":723},"obj":"Disease"},{"id":"684","span":{"begin":734,"end":742},"obj":"Species"},{"id":"690","span":{"begin":804,"end":813},"obj":"Disease"},{"id":"685","span":{"begin":843,"end":852},"obj":"Species"},{"id":"686","span":{"begin":857,"end":865},"obj":"Species"}],"attributes":[{"id":"A688","pred":"pubann:denotes","subj":"688","obj":"MESH:D007239"},{"id":"A681","pred":"pubann:denotes","subj":"681","obj":"Tax:2697049"},{"id":"A685","pred":"pubann:denotes","subj":"685","obj":"Tax:2697049"},{"id":"A687","pred":"pubann:denotes","subj":"687","obj":"MESH:D007239"},{"id":"A684","pred":"pubann:denotes","subj":"684","obj":"Tax:694009"},{"id":"A689","pred":"pubann:denotes","subj":"689","obj":"MESH:D007239"},{"id":"A679","pred":"pubann:denotes","subj":"679","obj":"Gene:103231639"},{"id":"A680","pred":"pubann:denotes","subj":"680","obj":"Tax:2697049"},{"id":"A691","pred":"pubann:denotes","subj":"691","obj":"CVCL:4582"},{"id":"A683","pred":"pubann:denotes","subj":"683","obj":"Tax:2697049"},{"id":"A682","pred":"pubann:denotes","subj":"682","obj":"Tax:694009"},{"id":"A690","pred":"pubann:denotes","subj":"690","obj":"MESH:D007239"},{"id":"A665","pred":"pubann:denotes","subj":"665","obj":"Tax:2697049"},{"id":"A686","pred":"pubann:denotes","subj":"686","obj":"Tax:694009"}],"text":"5 Recombinant type I IFN\n\n5.1 Hypothesis: IFNs play a role in anti-viral immunity\nType I IFNs play a primary role in the inhibition of viral replication through the coordination of anti-viral immune responses and modulation of inflammatory responses [24].\n\n5.2 Rational: Recombinant type I IFN can effectively inhibit SARS-CoV2 replication\nIn 24–48 h after infection, SARS-CoV2 replication reaches titer that causes the cytopathic effect in Vero E6 cells, which express ACE2 and thus are susceptible to SARS-CoV2 infection [25]. It is similar to the viral replication kinetics for SARS-CoV [25]. Pretreatment with recombinant type I IFN could effectively inhibit SARS-CoV2 replication at both 24 and 48 h after infection [25]. For SARS-CoV, such an effect was present at 24 h but absent at 48 h after infection [25]. The difference between SARS-CoV2 and SARS-CoV in response to type I IFN treatment may be due to differences in structural proteins of these viruses, including NSP3, ORF3b, and ORF6 [25]."}

{"project":"LitCovid-sample-UniProt","denotations":[{"id":"T1989","span":{"begin":931,"end":950},"obj":"Protein"},{"id":"T1992","span":{"begin":979,"end":983},"obj":"Protein"},{"id":"T2033","span":{"begin":996,"end":1000},"obj":"Protein"}],"attributes":[{"id":"A1989","pred":"uniprot_id","subj":"T1989","obj":"https://www.uniprot.org/uniprot/Q6LEG6"},{"id":"A1990","pred":"uniprot_id","subj":"T1989","obj":"https://www.uniprot.org/uniprot/Q04766"},{"id":"A1991","pred":"uniprot_id","subj":"T1989","obj":"https://www.uniprot.org/uniprot/Q04765"},{"id":"A1992","pred":"uniprot_id","subj":"T1992","obj":"https://www.uniprot.org/uniprot/Q9QNA7"},{"id":"A1993","pred":"uniprot_id","subj":"T1992","obj":"https://www.uniprot.org/uniprot/Q9PY95"},{"id":"A1994","pred":"uniprot_id","subj":"T1992","obj":"https://www.uniprot.org/uniprot/Q9ICB2"},{"id":"A1995","pred":"uniprot_id","subj":"T1992","obj":"https://www.uniprot.org/uniprot/Q91ME7"},{"id":"A1996","pred":"uniprot_id","subj":"T1992","obj":"https://www.uniprot.org/uniprot/Q8UZL8"},{"id":"A1997","pred":"uniprot_id","subj":"T1992","obj":"https://www.uniprot.org/uniprot/Q8B6X8"},{"id":"A1998","pred":"uniprot_id","subj":"T1992","obj":"https://www.uniprot.org/uniprot/Q8B6X7"},{"id":"A1999","pred":"uniprot_id","subj":"T1992","obj":"https://www.uniprot.org/uniprot/Q86504"},{"id":"A2000","pred":"uniprot_id","subj":"T1992","obj":"https://www.uniprot.org/uniprot/Q86196"},{"id":"A2001","pred":"uniprot_id","subj":"T1992","obj":"https://www.uniprot.org/uniprot/Q85014"},{"id":"A2002","pred":"uniprot_id","subj":"T1992","obj":"https://www.uniprot.org/uniprot/Q82054"},{"id":"A2003","pred":"uniprot_id","subj":"T1992","obj":"https://www.uniprot.org/uniprot/Q82053"},{"id":"A2004","pred":"uniprot_id","subj":"T1992","obj":"https://www.uniprot.org/uniprot/Q82052"},{"id":"A2005","pred":"uniprot_id","subj":"T1992","obj":"https://www.uniprot.org/uniprot/Q82051"},{"id":"A2006","pred":"uniprot_id","subj":"T1992","obj":"https://www.uniprot.org/uniprot/Q82050"},{"id":"A2007","pred":"uniprot_id","subj":"T1992","obj":"https://www.uniprot.org/uniprot/Q82049"},{"id":"A2008","pred":"uniprot_id","subj":"T1992","obj":"https://www.uniprot.org/uniprot/Q65701"},{"id":"A2009","pred":"uniprot_id","subj":"T1992","obj":"https://www.uniprot.org/uniprot/Q5Y9A9"},{"id":"A2010","pred":"uniprot_id","subj":"T1992","obj":"https://www.uniprot.org/uniprot/Q5K037"},{"id":"A2011","pred":"uniprot_id","subj":"T1992","obj":"https://www.uniprot.org/uniprot/Q45UF3"},{"id":"A2012","pred":"uniprot_id","subj":"T1992","obj":"https://www.uniprot.org/uniprot/Q3ZK63"},{"id":"A2013","pred":"uniprot_id","subj":"T1992","obj":"https://www.uniprot.org/uniprot/Q27PP2"},{"id":"A2014","pred":"uniprot_id","subj":"T1992","obj":"https://www.uniprot.org/uniprot/Q0H8C1"},{"id":"A2015","pred":"uniprot_id","subj":"T1992","obj":"https://www.uniprot.org/uniprot/Q00721"},{"id":"A2016","pred":"uniprot_id","subj":"T1992","obj":"https://www.uniprot.org/uniprot/P34717"},{"id":"A2017","pred":"uniprot_id","subj":"T1992","obj":"https://www.uniprot.org/uniprot/P27586"},{"id":"A2018","pred":"uniprot_id","subj":"T1992","obj":"https://www.uniprot.org/uniprot/P04514"},{"id":"A2019","pred":"uniprot_id","subj":"T1992","obj":"https://www.uniprot.org/uniprot/P03536"},{"id":"A2020","pred":"uniprot_id","subj":"T1992","obj":"https://www.uniprot.org/uniprot/B3SRX7"},{"id":"A2021","pred":"uniprot_id","subj":"T1992","obj":"https://www.uniprot.org/uniprot/B3SRW9"},{"id":"A2022","pred":"uniprot_id","subj":"T1992","obj":"https://www.uniprot.org/uniprot/B3SRV3"},{"id":"A2023","pred":"uniprot_id","subj":"T1992","obj":"https://www.uniprot.org/uniprot/B3SRU5"},{"id":"A2024","pred":"uniprot_id","subj":"T1992","obj":"https://www.uniprot.org/uniprot/B3SRS9"},{"id":"A2025","pred":"uniprot_id","subj":"T1992","obj":"https://www.uniprot.org/uniprot/B3SRS1"},{"id":"A2026","pred":"uniprot_id","subj":"T1992","obj":"https://www.uniprot.org/uniprot/B3SRR3"},{"id":"A2027","pred":"uniprot_id","subj":"T1992","obj":"https://www.uniprot.org/uniprot/B3SRQ5"},{"id":"A2028","pred":"uniprot_id","subj":"T1992","obj":"https://www.uniprot.org/uniprot/B2BRG4"},{"id":"A2029","pred":"uniprot_id","subj":"T1992","obj":"https://www.uniprot.org/uniprot/A4ZCW4"},{"id":"A2030","pred":"uniprot_id","subj":"T1992","obj":"https://www.uniprot.org/uniprot/A3DSK9"},{"id":"A2031","pred":"uniprot_id","subj":"T1992","obj":"https://www.uniprot.org/uniprot/A2T3N5"},{"id":"A2032","pred":"uniprot_id","subj":"T1992","obj":"https://www.uniprot.org/uniprot/A1YTU9"},{"id":"A2033","pred":"uniprot_id","subj":"T2033","obj":"https://www.uniprot.org/uniprot/P51707"},{"id":"A2034","pred":"uniprot_id","subj":"T2033","obj":"https://www.uniprot.org/uniprot/P42541"},{"id":"A2035","pred":"uniprot_id","subj":"T2033","obj":"https://www.uniprot.org/uniprot/P0DTC6"}],"text":"5 Recombinant type I IFN\n\n5.1 Hypothesis: IFNs play a role in anti-viral immunity\nType I IFNs play a primary role in the inhibition of viral replication through the coordination of anti-viral immune responses and modulation of inflammatory responses [24].\n\n5.2 Rational: Recombinant type I IFN can effectively inhibit SARS-CoV2 replication\nIn 24–48 h after infection, SARS-CoV2 replication reaches titer that causes the cytopathic effect in Vero E6 cells, which express ACE2 and thus are susceptible to SARS-CoV2 infection [25]. It is similar to the viral replication kinetics for SARS-CoV [25]. Pretreatment with recombinant type I IFN could effectively inhibit SARS-CoV2 replication at both 24 and 48 h after infection [25]. For SARS-CoV, such an effect was present at 24 h but absent at 48 h after infection [25]. The difference between SARS-CoV2 and SARS-CoV in response to type I IFN treatment may be due to differences in structural proteins of these viruses, including NSP3, ORF3b, and ORF6 [25]."}

{"project":"LitCovid-sample-Enju","denotations":[{"id":"T52733","span":{"begin":0,"end":1},"obj":"CD"},{"id":"T83488","span":{"begin":3,"end":14},"obj":"JJ"},{"id":"T93217","span":{"begin":15,"end":19},"obj":"NN"},{"id":"T64716","span":{"begin":20,"end":21},"obj":"CD"},{"id":"T68579","span":{"begin":22,"end":25},"obj":"NN"},{"id":"T12001","span":{"begin":27,"end":30},"obj":"CD"},{"id":"T9969","span":{"begin":32,"end":42},"obj":"NN"},{"id":"T15939","span":{"begin":42,"end":43},"obj":"-COLON-"},{"id":"T64893","span":{"begin":44,"end":48},"obj":"NNS"},{"id":"T64532","span":{"begin":49,"end":53},"obj":"VBP"},{"id":"T66496","span":{"begin":54,"end":55},"obj":"DT"},{"id":"T99130","span":{"begin":56,"end":60},"obj":"NN"},{"id":"T16405","span":{"begin":61,"end":63},"obj":"IN"},{"id":"T11399","span":{"begin":64,"end":74},"obj":"JJ"},{"id":"T89696","span":{"begin":75,"end":83},"obj":"NN"},{"id":"T96681","span":{"begin":84,"end":88},"obj":"NN"},{"id":"T4789","span":{"begin":89,"end":90},"obj":"CD"},{"id":"T85645","span":{"begin":91,"end":95},"obj":"NNS"},{"id":"T76626","span":{"begin":96,"end":100},"obj":"VBP"},{"id":"T51847","span":{"begin":101,"end":102},"obj":"DT"},{"id":"T51548","span":{"begin":103,"end":110},"obj":"JJ"},{"id":"T78533","span":{"begin":111,"end":115},"obj":"NN"},{"id":"T65875","span":{"begin":116,"end":118},"obj":"IN"},{"id":"T16934","span":{"begin":119,"end":122},"obj":"DT"},{"id":"T59480","span":{"begin":123,"end":133},"obj":"NN"},{"id":"T64120","span":{"begin":134,"end":136},"obj":"IN"},{"id":"T42209","span":{"begin":137,"end":142},"obj":"JJ"},{"id":"T92412","span":{"begin":143,"end":154},"obj":"NN"},{"id":"T19053","span":{"begin":155,"end":162},"obj":"IN"},{"id":"T85138","span":{"begin":163,"end":166},"obj":"DT"},{"id":"T89603","span":{"begin":167,"end":179},"obj":"NN"},{"id":"T52542","span":{"begin":180,"end":182},"obj":"IN"},{"id":"T13645","span":{"begin":183,"end":193},"obj":"JJ"},{"id":"T39632","span":{"begin":194,"end":200},"obj":"JJ"},{"id":"T42144","span":{"begin":201,"end":210},"obj":"NNS"},{"id":"T54149","span":{"begin":211,"end":214},"obj":"CC"},{"id":"T13001","span":{"begin":215,"end":225},"obj":"NN"},{"id":"T2287","span":{"begin":226,"end":228},"obj":"IN"},{"id":"T72730","span":{"begin":229,"end":241},"obj":"JJ"},{"id":"T37912","span":{"begin":242,"end":251},"obj":"NNS"},{"id":"T64464","span":{"begin":252,"end":253},"obj":"-LRB-"},{"id":"T89396","span":{"begin":253,"end":255},"obj":"CD"},{"id":"T17915","span":{"begin":255,"end":256},"obj":"-RRB-"},{"id":"T44068","span":{"begin":259,"end":262},"obj":"CD"},{"id":"T95208","span":{"begin":264,"end":272},"obj":"NNP"},{"id":"T91019","span":{"begin":272,"end":273},"obj":"-COLON-"},{"id":"T95927","span":{"begin":274,"end":285},"obj":"JJ"},{"id":"T3712","span":{"begin":286,"end":290},"obj":"NN"},{"id":"T46872","span":{"begin":291,"end":292},"obj":"CD"},{"id":"T95232","span":{"begin":293,"end":296},"obj":"NN"},{"id":"T83801","span":{"begin":297,"end":300},"obj":"MD"},{"id":"T31121","span":{"begin":301,"end":312},"obj":"RB"},{"id":"T50200","span":{"begin":313,"end":320},"obj":"VB"},{"id":"T51383","span":{"begin":321,"end":330},"obj":"NN"},{"id":"T97492","span":{"begin":331,"end":342},"obj":"NN"},{"id":"T96177","span":{"begin":343,"end":345},"obj":"IN"},{"id":"T72452","span":{"begin":346,"end":353},"obj":"NN"},{"id":"T50493","span":{"begin":354,"end":359},"obj":"IN"},{"id":"T17096","span":{"begin":360,"end":369},"obj":"NN"},{"id":"T97012","span":{"begin":369,"end":370},"obj":"-COMMA-"},{"id":"T67170","span":{"begin":371,"end":380},"obj":"NN"},{"id":"T9761","span":{"begin":381,"end":392},"obj":"NN"},{"id":"T69880","span":{"begin":393,"end":400},"obj":"VBZ"},{"id":"T9709","span":{"begin":401,"end":406},"obj":"NN"},{"id":"T49785","span":{"begin":407,"end":411},"obj":"WDT"},{"id":"T71708","span":{"begin":412,"end":418},"obj":"VBZ"},{"id":"T52777","span":{"begin":419,"end":422},"obj":"DT"},{"id":"T56623","span":{"begin":423,"end":433},"obj":"JJ"},{"id":"T87850","span":{"begin":434,"end":440},"obj":"NN"},{"id":"T47272","span":{"begin":441,"end":443},"obj":"IN"},{"id":"T71726","span":{"begin":444,"end":448},"obj":"NN"},{"id":"T42629","span":{"begin":449,"end":451},"obj":"NN"},{"id":"T73531","span":{"begin":452,"end":457},"obj":"NNS"},{"id":"T60353","span":{"begin":457,"end":458},"obj":"-COMMA-"},{"id":"T83400","span":{"begin":459,"end":464},"obj":"WDT"},{"id":"T80948","span":{"begin":465,"end":472},"obj":"VBP"},{"id":"T12338","span":{"begin":473,"end":477},"obj":"NN"},{"id":"T60658","span":{"begin":478,"end":481},"obj":"CC"},{"id":"T41368","span":{"begin":482,"end":486},"obj":"RB"},{"id":"T89464","span":{"begin":487,"end":490},"obj":"VBP"},{"id":"T62340","span":{"begin":491,"end":502},"obj":"JJ"},{"id":"T6873","span":{"begin":503,"end":505},"obj":"TO"},{"id":"T68175","span":{"begin":506,"end":515},"obj":"NN"},{"id":"T16296","span":{"begin":516,"end":525},"obj":"NN"},{"id":"T12529","span":{"begin":526,"end":527},"obj":"-LRB-"},{"id":"T55131","span":{"begin":527,"end":529},"obj":"CD"},{"id":"T28678","span":{"begin":529,"end":530},"obj":"-RRB-"},{"id":"T52876","span":{"begin":532,"end":534},"obj":"PRP"},{"id":"T21084","span":{"begin":535,"end":537},"obj":"VBZ"},{"id":"T70918","span":{"begin":538,"end":545},"obj":"JJ"},{"id":"T20327","span":{"begin":546,"end":548},"obj":"TO"},{"id":"T13471","span":{"begin":549,"end":552},"obj":"DT"},{"id":"T26039","span":{"begin":553,"end":558},"obj":"JJ"},{"id":"T64125","span":{"begin":559,"end":570},"obj":"NN"},{"id":"T62855","span":{"begin":571,"end":579},"obj":"NNS"},{"id":"T68614","span":{"begin":580,"end":583},"obj":"IN"},{"id":"T64958","span":{"begin":584,"end":592},"obj":"NN"},{"id":"T62199","span":{"begin":593,"end":594},"obj":"-LRB-"},{"id":"T27403","span":{"begin":594,"end":596},"obj":"CD"},{"id":"T34963","span":{"begin":596,"end":597},"obj":"-RRB-"},{"id":"T49689","span":{"begin":599,"end":611},"obj":"NN"},{"id":"T74739","span":{"begin":612,"end":616},"obj":"IN"},{"id":"T62356","span":{"begin":617,"end":628},"obj":"JJ"},{"id":"T67333","span":{"begin":629,"end":633},"obj":"NN"},{"id":"T31833","span":{"begin":634,"end":635},"obj":"CD"},{"id":"T78772","span":{"begin":636,"end":639},"obj":"NN"},{"id":"T57406","span":{"begin":640,"end":645},"obj":"MD"},{"id":"T5100","span":{"begin":646,"end":657},"obj":"RB"},{"id":"T32529","span":{"begin":658,"end":665},"obj":"VB"},{"id":"T31501","span":{"begin":666,"end":675},"obj":"NN"},{"id":"T43668","span":{"begin":676,"end":687},"obj":"NN"},{"id":"T86722","span":{"begin":688,"end":690},"obj":"IN"},{"id":"T26971","span":{"begin":691,"end":695},"obj":"CC"},{"id":"T35627","span":{"begin":696,"end":698},"obj":"CD"},{"id":"T29701","span":{"begin":699,"end":702},"obj":"CC"},{"id":"T48153","span":{"begin":703,"end":707},"obj":"NN"},{"id":"T93874","span":{"begin":708,"end":713},"obj":"IN"},{"id":"T7550","span":{"begin":714,"end":723},"obj":"NN"},{"id":"T23827","span":{"begin":724,"end":725},"obj":"-LRB-"},{"id":"T6071","span":{"begin":725,"end":727},"obj":"CD"},{"id":"T91011","span":{"begin":727,"end":728},"obj":"-RRB-"},{"id":"T51029","span":{"begin":730,"end":733},"obj":"IN"},{"id":"T64526","span":{"begin":734,"end":742},"obj":"NN"},{"id":"T41819","span":{"begin":742,"end":743},"obj":"-COMMA-"},{"id":"T5764","span":{"begin":744,"end":748},"obj":"PDT"},{"id":"T79954","span":{"begin":749,"end":751},"obj":"DT"},{"id":"T48924","span":{"begin":752,"end":758},"obj":"NN"},{"id":"T40034","span":{"begin":759,"end":762},"obj":"VBD"},{"id":"T1935","span":{"begin":763,"end":770},"obj":"JJ"},{"id":"T31311","span":{"begin":771,"end":773},"obj":"IN"},{"id":"T94385","span":{"begin":774,"end":778},"obj":"CD"},{"id":"T84543","span":{"begin":779,"end":782},"obj":"CC"},{"id":"T64490","span":{"begin":783,"end":789},"obj":"JJ"},{"id":"T33679","span":{"begin":790,"end":792},"obj":"IN"},{"id":"T68271","span":{"begin":793,"end":797},"obj":"NN"},{"id":"T69307","span":{"begin":798,"end":803},"obj":"IN"},{"id":"T51672","span":{"begin":804,"end":813},"obj":"NN"},{"id":"T85433","span":{"begin":814,"end":815},"obj":"-LRB-"},{"id":"T72350","span":{"begin":815,"end":817},"obj":"CD"},{"id":"T63406","span":{"begin":817,"end":818},"obj":"-RRB-"},{"id":"T46096","span":{"begin":820,"end":823},"obj":"DT"},{"id":"T71403","span":{"begin":824,"end":834},"obj":"NN"},{"id":"T17651","span":{"begin":835,"end":842},"obj":"IN"},{"id":"T77482","span":{"begin":843,"end":852},"obj":"NN"},{"id":"T6733","span":{"begin":853,"end":856},"obj":"CC"},{"id":"T6622","span":{"begin":857,"end":865},"obj":"NN"},{"id":"T66580","span":{"begin":866,"end":868},"obj":"IN"},{"id":"T74975","span":{"begin":869,"end":877},"obj":"NN"},{"id":"T1853","span":{"begin":878,"end":880},"obj":"TO"},{"id":"T87892","span":{"begin":881,"end":885},"obj":"NN"},{"id":"T83308","span":{"begin":886,"end":887},"obj":"CD"},{"id":"T81934","span":{"begin":888,"end":891},"obj":"NN"},{"id":"T42652","span":{"begin":892,"end":901},"obj":"NN"},{"id":"T91527","span":{"begin":902,"end":905},"obj":"MD"},{"id":"T42839","span":{"begin":906,"end":908},"obj":"VB"},{"id":"T98810","span":{"begin":909,"end":912},"obj":"JJ"},{"id":"T31126","span":{"begin":913,"end":915},"obj":"TO"},{"id":"T23141","span":{"begin":916,"end":927},"obj":"NNS"},{"id":"T45488","span":{"begin":928,"end":930},"obj":"IN"},{"id":"T39296","span":{"begin":931,"end":941},"obj":"JJ"},{"id":"T12723","span":{"begin":942,"end":950},"obj":"NNS"},{"id":"T40582","span":{"begin":951,"end":953},"obj":"IN"},{"id":"T48639","span":{"begin":954,"end":959},"obj":"DT"},{"id":"T20513","span":{"begin":960,"end":967},"obj":"NNS"},{"id":"T37519","span":{"begin":967,"end":968},"obj":"-COMMA-"},{"id":"T18237","span":{"begin":969,"end":978},"obj":"VBG"},{"id":"T17094","span":{"begin":979,"end":983},"obj":"NN"},{"id":"T86991","span":{"begin":983,"end":984},"obj":"-COMMA-"},{"id":"T14810","span":{"begin":985,"end":990},"obj":"NN"},{"id":"T9269","span":{"begin":990,"end":991},"obj":"-COMMA-"},{"id":"T18064","span":{"begin":992,"end":995},"obj":"CC"},{"id":"T40695","span":{"begin":996,"end":1000},"obj":"NN"},{"id":"T59456","span":{"begin":1001,"end":1002},"obj":"-LRB-"},{"id":"T34145","span":{"begin":1002,"end":1004},"obj":"CD"},{"id":"T98303","span":{"begin":1004,"end":1005},"obj":"-RRB-"}],"relations":[{"id":"R49535","pred":"arg1Of","subj":"T99130","obj":"T66496"},{"id":"R82137","pred":"arg1Of","subj":"T64532","obj":"T16405"},{"id":"R93910","pred":"arg2Of","subj":"T89696","obj":"T16405"},{"id":"R53989","pred":"arg1Of","subj":"T89696","obj":"T11399"},{"id":"R24484","pred":"arg1Of","subj":"T85645","obj":"T96681"},{"id":"R82882","pred":"arg1Of","subj":"T85645","obj":"T4789"},{"id":"R80452","pred":"arg1Of","subj":"T85645","obj":"T76626"},{"id":"R9839","pred":"arg2Of","subj":"T78533","obj":"T76626"},{"id":"R78526","pred":"arg1Of","subj":"T78533","obj":"T51847"},{"id":"R6704","pred":"arg1Of","subj":"T78533","obj":"T51548"},{"id":"R74996","pred":"arg1Of","subj":"T76626","obj":"T65875"},{"id":"R31420","pred":"arg1Of","subj":"T69880","obj":"T96177"},{"id":"R8938","pred":"arg2Of","subj":"T72452","obj":"T96177"},{"id":"R22070","pred":"arg1Of","subj":"T72452","obj":"T50493"},{"id":"R29558","pred":"arg2Of","subj":"T17096","obj":"T50493"},{"id":"R81743","pred":"arg1Of","subj":"T69880","obj":"T97012"},{"id":"R54619","pred":"arg1Of","subj":"T9761","obj":"T67170"},{"id":"R28733","pred":"arg1Of","subj":"T9761","obj":"T69880"},{"id":"R54888","pred":"arg2Of","subj":"T9709","obj":"T69880"},{"id":"R54019","pred":"arg1Of","subj":"T9709","obj":"T49785"},{"id":"R2019","pred":"arg1Of","subj":"T9709","obj":"T71708"},{"id":"R69166","pred":"arg2Of","subj":"T87850","obj":"T71708"},{"id":"R70600","pred":"arg1Of","subj":"T87850","obj":"T52777"},{"id":"R54949","pred":"arg1Of","subj":"T87850","obj":"T56623"},{"id":"R44193","pred":"arg1Of","subj":"T68579","obj":"T52733"},{"id":"R5826","pred":"arg1Of","subj":"T68579","obj":"T83488"},{"id":"R80234","pred":"arg1Of","subj":"T68579","obj":"T93217"},{"id":"R96417","pred":"arg1Of","subj":"T68579","obj":"T64716"},{"id":"R50529","pred":"arg1Of","subj":"T9969","obj":"T12001"},{"id":"R73746","pred":"arg1Of","subj":"T9969","obj":"T15939"},{"id":"R48761","pred":"arg2Of","subj":"T64532","obj":"T15939"},{"id":"R11011","pred":"arg1Of","subj":"T64893","obj":"T64532"},{"id":"R56923","pred":"arg2Of","subj":"T99130","obj":"T64532"},{"id":"R7798","pred":"arg2Of","subj":"T59480","obj":"T65875"},{"id":"R26292","pred":"arg1Of","subj":"T59480","obj":"T16934"},{"id":"R3018","pred":"arg1Of","subj":"T59480","obj":"T64120"},{"id":"R88840","pred":"arg2Of","subj":"T92412","obj":"T64120"},{"id":"R43315","pred":"arg1Of","subj":"T92412","obj":"T42209"},{"id":"R45666","pred":"arg1Of","subj":"T76626","obj":"T19053"},{"id":"R41012","pred":"arg2Of","subj":"T54149","obj":"T19053"},{"id":"R49957","pred":"arg1Of","subj":"T54149","obj":"T85138"},{"id":"R10665","pred":"arg1Of","subj":"T89603","obj":"T52542"},{"id":"R3748","pred":"arg2Of","subj":"T42144","obj":"T52542"},{"id":"R96444","pred":"arg1Of","subj":"T42144","obj":"T13645"},{"id":"R11270","pred":"arg1Of","subj":"T42144","obj":"T39632"},{"id":"R93882","pred":"arg1Of","subj":"T89603","obj":"T54149"},{"id":"R64051","pred":"arg2Of","subj":"T13001","obj":"T54149"},{"id":"R35227","pred":"arg1Of","subj":"T13001","obj":"T2287"},{"id":"R46504","pred":"arg2Of","subj":"T37912","obj":"T2287"},{"id":"R49745","pred":"arg1Of","subj":"T37912","obj":"T72730"},{"id":"R59902","pred":"arg1Of","subj":"T76626","obj":"T64464"},{"id":"R73394","pred":"arg2Of","subj":"T89396","obj":"T64464"},{"id":"R27076","pred":"arg3Of","subj":"T17915","obj":"T64464"},{"id":"R12484","pred":"arg1Of","subj":"T95208","obj":"T44068"},{"id":"R35124","pred":"arg1Of","subj":"T95208","obj":"T91019"},{"id":"R50751","pred":"arg1Of","subj":"T95232","obj":"T95927"},{"id":"R74572","pred":"arg1Of","subj":"T95232","obj":"T3712"},{"id":"R58753","pred":"arg1Of","subj":"T95232","obj":"T46872"},{"id":"R16030","pred":"arg1Of","subj":"T95232","obj":"T83801"},{"id":"R78959","pred":"arg2Of","subj":"T50200","obj":"T83801"},{"id":"R77408","pred":"arg1Of","subj":"T50200","obj":"T31121"},{"id":"R98880","pred":"arg1Of","subj":"T95232","obj":"T50200"},{"id":"R90780","pred":"arg2Of","subj":"T97492","obj":"T50200"},{"id":"R70416","pred":"arg1Of","subj":"T97492","obj":"T51383"},{"id":"R67236","pred":"arg1Of","subj":"T71708","obj":"T47272"},{"id":"R90604","pred":"arg2Of","subj":"T73531","obj":"T47272"},{"id":"R51483","pred":"arg1Of","subj":"T73531","obj":"T71726"},{"id":"R13941","pred":"arg1Of","subj":"T73531","obj":"T42629"},{"id":"R47369","pred":"arg1Of","subj":"T73531","obj":"T60353"},{"id":"R77344","pred":"arg1Of","subj":"T73531","obj":"T83400"},{"id":"R51996","pred":"arg1Of","subj":"T73531","obj":"T80948"},{"id":"R29937","pred":"arg2Of","subj":"T12338","obj":"T80948"},{"id":"R56727","pred":"arg1Of","subj":"T80948","obj":"T60658"},{"id":"R89880","pred":"arg2Of","subj":"T89464","obj":"T60658"},{"id":"R41139","pred":"arg1Of","subj":"T89464","obj":"T41368"},{"id":"R40674","pred":"arg1Of","subj":"T73531","obj":"T89464"},{"id":"R2313","pred":"arg2Of","subj":"T62340","obj":"T89464"},{"id":"R71574","pred":"arg1Of","subj":"T73531","obj":"T62340"},{"id":"R18320","pred":"arg1Of","subj":"T62340","obj":"T6873"},{"id":"R10483","pred":"arg2Of","subj":"T16296","obj":"T6873"},{"id":"R64279","pred":"arg1Of","subj":"T16296","obj":"T68175"},{"id":"R82228","pred":"arg1Of","subj":"T89464","obj":"T12529"},{"id":"R14351","pred":"arg2Of","subj":"T55131","obj":"T12529"},{"id":"R89760","pred":"arg3Of","subj":"T28678","obj":"T12529"},{"id":"R98431","pred":"arg1Of","subj":"T52876","obj":"T21084"},{"id":"R14327","pred":"arg2Of","subj":"T70918","obj":"T21084"},{"id":"R4320","pred":"arg1Of","subj":"T52876","obj":"T70918"},{"id":"R34375","pred":"arg1Of","subj":"T70918","obj":"T20327"},{"id":"R71339","pred":"arg2Of","subj":"T62855","obj":"T20327"},{"id":"R35190","pred":"arg1Of","subj":"T62855","obj":"T13471"},{"id":"R34673","pred":"arg1Of","subj":"T62855","obj":"T26039"},{"id":"R67158","pred":"arg1Of","subj":"T62855","obj":"T64125"},{"id":"R90913","pred":"arg1Of","subj":"T70918","obj":"T68614"},{"id":"R5275","pred":"arg2Of","subj":"T64958","obj":"T68614"},{"id":"R43068","pred":"arg1Of","subj":"T64958","obj":"T62199"},{"id":"R10807","pred":"arg2Of","subj":"T27403","obj":"T62199"},{"id":"R91008","pred":"arg3Of","subj":"T34963","obj":"T62199"},{"id":"R68776","pred":"arg1Of","subj":"T49689","obj":"T74739"},{"id":"R59690","pred":"arg2Of","subj":"T78772","obj":"T74739"},{"id":"R64010","pred":"arg1Of","subj":"T78772","obj":"T62356"},{"id":"R73596","pred":"arg1Of","subj":"T78772","obj":"T67333"},{"id":"R44930","pred":"arg1Of","subj":"T78772","obj":"T31833"},{"id":"R49184","pred":"arg1Of","subj":"T49689","obj":"T57406"},{"id":"R80908","pred":"arg2Of","subj":"T32529","obj":"T57406"},{"id":"R7756","pred":"arg1Of","subj":"T32529","obj":"T5100"},{"id":"R41655","pred":"arg1Of","subj":"T49689","obj":"T32529"},{"id":"R47659","pred":"arg2Of","subj":"T43668","obj":"T32529"},{"id":"R36370","pred":"arg1Of","subj":"T43668","obj":"T31501"},{"id":"R34213","pred":"arg1Of","subj":"T32529","obj":"T86722"},{"id":"R26206","pred":"arg2Of","subj":"T29701","obj":"T86722"},{"id":"R82903","pred":"arg1Of","subj":"T29701","obj":"T26971"},{"id":"R75547","pred":"arg1Of","subj":"T35627","obj":"T29701"},{"id":"R90827","pred":"arg2Of","subj":"T48153","obj":"T29701"},{"id":"R69068","pred":"arg1Of","subj":"T32529","obj":"T93874"},{"id":"R47977","pred":"arg2Of","subj":"T7550","obj":"T93874"},{"id":"R38076","pred":"arg1Of","subj":"T7550","obj":"T23827"},{"id":"R72421","pred":"arg2Of","subj":"T6071","obj":"T23827"},{"id":"R2860","pred":"arg3Of","subj":"T91011","obj":"T23827"},{"id":"R21012","pred":"arg1Of","subj":"T40034","obj":"T51029"},{"id":"R42425","pred":"arg2Of","subj":"T64526","obj":"T51029"},{"id":"R88091","pred":"arg1Of","subj":"T40034","obj":"T41819"},{"id":"R54495","pred":"arg1Of","subj":"T48924","obj":"T5764"},{"id":"R26625","pred":"arg1Of","subj":"T48924","obj":"T79954"},{"id":"R41534","pred":"arg1Of","subj":"T48924","obj":"T40034"},{"id":"R24883","pred":"arg2Of","subj":"T84543","obj":"T40034"},{"id":"R86398","pred":"arg1Of","subj":"T48924","obj":"T1935"},{"id":"R81876","pred":"arg1Of","subj":"T1935","obj":"T31311"},{"id":"R72270","pred":"arg2Of","subj":"T94385","obj":"T31311"},{"id":"R12851","pred":"arg1Of","subj":"T1935","obj":"T84543"},{"id":"R60363","pred":"arg2Of","subj":"T64490","obj":"T84543"},{"id":"R81621","pred":"arg1Of","subj":"T48924","obj":"T64490"},{"id":"R79664","pred":"arg1Of","subj":"T84543","obj":"T33679"},{"id":"R9487","pred":"arg2Of","subj":"T68271","obj":"T33679"},{"id":"R71731","pred":"arg1Of","subj":"T68271","obj":"T69307"},{"id":"R56025","pred":"arg2Of","subj":"T51672","obj":"T69307"},{"id":"R2152","pred":"arg1Of","subj":"T51672","obj":"T85433"},{"id":"R22284","pred":"arg2Of","subj":"T72350","obj":"T85433"},{"id":"R9566","pred":"arg3Of","subj":"T63406","obj":"T85433"},{"id":"R51347","pred":"arg1Of","subj":"T71403","obj":"T46096"},{"id":"R4839","pred":"arg1Of","subj":"T71403","obj":"T17651"},{"id":"R32316","pred":"arg2Of","subj":"T6733","obj":"T17651"},{"id":"R84108","pred":"arg1Of","subj":"T77482","obj":"T6733"},{"id":"R18562","pred":"arg2Of","subj":"T6622","obj":"T6733"},{"id":"R2587","pred":"arg1Of","subj":"T6733","obj":"T66580"},{"id":"R24267","pred":"arg2Of","subj":"T74975","obj":"T66580"},{"id":"R82007","pred":"arg1Of","subj":"T74975","obj":"T1853"},{"id":"R35751","pred":"arg2Of","subj":"T42652","obj":"T1853"},{"id":"R70872","pred":"arg1Of","subj":"T42652","obj":"T87892"},{"id":"R16675","pred":"arg1Of","subj":"T42652","obj":"T83308"},{"id":"R93961","pred":"arg1Of","subj":"T42652","obj":"T81934"},{"id":"R17630","pred":"arg1Of","subj":"T71403","obj":"T91527"},{"id":"R18684","pred":"arg2Of","subj":"T42839","obj":"T91527"},{"id":"R22926","pred":"arg1Of","subj":"T71403","obj":"T42839"},{"id":"R74216","pred":"arg2Of","subj":"T31126","obj":"T42839"},{"id":"R18552","pred":"arg1Of","subj":"T31126","obj":"T98810"},{"id":"R78491","pred":"arg1Of","subj":"T71403","obj":"T31126"},{"id":"R99441","pred":"arg2Of","subj":"T23141","obj":"T31126"},{"id":"R87106","pred":"arg1Of","subj":"T23141","obj":"T45488"},{"id":"R95354","pred":"arg2Of","subj":"T12723","obj":"T45488"},{"id":"R28120","pred":"arg1Of","subj":"T12723","obj":"T39296"},{"id":"R78454","pred":"arg1Of","subj":"T12723","obj":"T40582"},{"id":"R26738","pred":"arg2Of","subj":"T20513","obj":"T40582"},{"id":"R35077","pred":"arg1Of","subj":"T20513","obj":"T48639"},{"id":"R70559","pred":"arg1Of","subj":"T12723","obj":"T37519"},{"id":"R50810","pred":"arg1Of","subj":"T12723","obj":"T18237"},{"id":"R8147","pred":"arg2Of","subj":"T18064","obj":"T18237"},{"id":"R72409","pred":"arg1Of","subj":"T17094","obj":"T86991"},{"id":"R12802","pred":"arg2Of","subj":"T14810","obj":"T86991"},{"id":"R29123","pred":"arg1Of","subj":"T18064","obj":"T9269"},{"id":"R68379","pred":"arg1Of","subj":"T86991","obj":"T18064"},{"id":"R4978","pred":"arg2Of","subj":"T40695","obj":"T18064"},{"id":"R22872","pred":"arg1Of","subj":"T18064","obj":"T59456"},{"id":"R60583","pred":"arg2Of","subj":"T34145","obj":"T59456"},{"id":"R50503","pred":"arg3Of","subj":"T98303","obj":"T59456"}],"text":"5 Recombinant type I IFN\n\n5.1 Hypothesis: IFNs play a role in anti-viral immunity\nType I IFNs play a primary role in the inhibition of viral replication through the coordination of anti-viral immune responses and modulation of inflammatory responses [24].\n\n5.2 Rational: Recombinant type I IFN can effectively inhibit SARS-CoV2 replication\nIn 24–48 h after infection, SARS-CoV2 replication reaches titer that causes the cytopathic effect in Vero E6 cells, which express ACE2 and thus are susceptible to SARS-CoV2 infection [25]. It is similar to the viral replication kinetics for SARS-CoV [25]. Pretreatment with recombinant type I IFN could effectively inhibit SARS-CoV2 replication at both 24 and 48 h after infection [25]. For SARS-CoV, such an effect was present at 24 h but absent at 48 h after infection [25]. The difference between SARS-CoV2 and SARS-CoV in response to type I IFN treatment may be due to differences in structural proteins of these viruses, including NSP3, ORF3b, and ORF6 [25]."}

{"project":"LitCovid-sample-PD-GO-BP-0","denotations":[{"id":"T22","span":{"begin":123,"end":154},"obj":"http://purl.obolibrary.org/obo/GO_1903901"},{"id":"T23","span":{"begin":137,"end":154},"obj":"http://purl.obolibrary.org/obo/GO_0019058"},{"id":"T24","span":{"begin":137,"end":154},"obj":"http://purl.obolibrary.org/obo/GO_0019079"},{"id":"T25","span":{"begin":194,"end":210},"obj":"http://purl.obolibrary.org/obo/GO_0006955"},{"id":"T26","span":{"begin":229,"end":251},"obj":"http://purl.obolibrary.org/obo/GO_0006954"},{"id":"T27","span":{"begin":553,"end":570},"obj":"http://purl.obolibrary.org/obo/GO_0019058"},{"id":"T28","span":{"begin":553,"end":570},"obj":"http://purl.obolibrary.org/obo/GO_0019079"},{"id":"T29","span":{"begin":869,"end":891},"obj":"http://purl.obolibrary.org/obo/GO_0034340"}],"text":"5 Recombinant type I IFN\n\n5.1 Hypothesis: IFNs play a role in anti-viral immunity\nType I IFNs play a primary role in the inhibition of viral replication through the coordination of anti-viral immune responses and modulation of inflammatory responses [24].\n\n5.2 Rational: Recombinant type I IFN can effectively inhibit SARS-CoV2 replication\nIn 24–48 h after infection, SARS-CoV2 replication reaches titer that causes the cytopathic effect in Vero E6 cells, which express ACE2 and thus are susceptible to SARS-CoV2 infection [25]. It is similar to the viral replication kinetics for SARS-CoV [25]. Pretreatment with recombinant type I IFN could effectively inhibit SARS-CoV2 replication at both 24 and 48 h after infection [25]. For SARS-CoV, such an effect was present at 24 h but absent at 48 h after infection [25]. The difference between SARS-CoV2 and SARS-CoV in response to type I IFN treatment may be due to differences in structural proteins of these viruses, including NSP3, ORF3b, and ORF6 [25]."}

{"project":"LitCovid-sample-PD-FMA","denotations":[{"id":"T147","span":{"begin":452,"end":457},"obj":"Body_part"},{"id":"T148","span":{"begin":942,"end":950},"obj":"Body_part"}],"attributes":[{"id":"A147","pred":"fma_id","subj":"T147","obj":"http://purl.org/sig/ont/fma/fma68646"},{"id":"A148","pred":"fma_id","subj":"T148","obj":"http://purl.org/sig/ont/fma/fma67257"}],"text":"5 Recombinant type I IFN\n\n5.1 Hypothesis: IFNs play a role in anti-viral immunity\nType I IFNs play a primary role in the inhibition of viral replication through the coordination of anti-viral immune responses and modulation of inflammatory responses [24].\n\n5.2 Rational: Recombinant type I IFN can effectively inhibit SARS-CoV2 replication\nIn 24–48 h after infection, SARS-CoV2 replication reaches titer that causes the cytopathic effect in Vero E6 cells, which express ACE2 and thus are susceptible to SARS-CoV2 infection [25]. It is similar to the viral replication kinetics for SARS-CoV [25]. Pretreatment with recombinant type I IFN could effectively inhibit SARS-CoV2 replication at both 24 and 48 h after infection [25]. For SARS-CoV, such an effect was present at 24 h but absent at 48 h after infection [25]. The difference between SARS-CoV2 and SARS-CoV in response to type I IFN treatment may be due to differences in structural proteins of these viruses, including NSP3, ORF3b, and ORF6 [25]."}

{"project":"LitCovid-sample-PD-MONDO","denotations":[{"id":"T134","span":{"begin":321,"end":330},"obj":"Disease"},{"id":"T135","span":{"begin":360,"end":369},"obj":"Disease"},{"id":"T136","span":{"begin":371,"end":380},"obj":"Disease"},{"id":"T137","span":{"begin":506,"end":515},"obj":"Disease"},{"id":"T138","span":{"begin":516,"end":525},"obj":"Disease"},{"id":"T139","span":{"begin":584,"end":592},"obj":"Disease"},{"id":"T140","span":{"begin":666,"end":675},"obj":"Disease"},{"id":"T141","span":{"begin":714,"end":723},"obj":"Disease"},{"id":"T142","span":{"begin":734,"end":742},"obj":"Disease"},{"id":"T143","span":{"begin":804,"end":813},"obj":"Disease"},{"id":"T144","span":{"begin":843,"end":852},"obj":"Disease"},{"id":"T145","span":{"begin":857,"end":865},"obj":"Disease"}],"attributes":[{"id":"A141","pred":"mondo_id","subj":"T141","obj":"http://purl.obolibrary.org/obo/MONDO_0005550"},{"id":"A142","pred":"mondo_id","subj":"T142","obj":"http://purl.obolibrary.org/obo/MONDO_0005091"},{"id":"A139","pred":"mondo_id","subj":"T139","obj":"http://purl.obolibrary.org/obo/MONDO_0005091"},{"id":"A140","pred":"mondo_id","subj":"T140","obj":"http://purl.obolibrary.org/obo/MONDO_0100096"},{"id":"A136","pred":"mondo_id","subj":"T136","obj":"http://purl.obolibrary.org/obo/MONDO_0100096"},{"id":"A143","pred":"mondo_id","subj":"T143","obj":"http://purl.obolibrary.org/obo/MONDO_0005550"},{"id":"A144","pred":"mondo_id","subj":"T144","obj":"http://purl.obolibrary.org/obo/MONDO_0100096"},{"id":"A134","pred":"mondo_id","subj":"T134","obj":"http://purl.obolibrary.org/obo/MONDO_0100096"},{"id":"A135","pred":"mondo_id","subj":"T135","obj":"http://purl.obolibrary.org/obo/MONDO_0005550"},{"id":"A145","pred":"mondo_id","subj":"T145","obj":"http://purl.obolibrary.org/obo/MONDO_0005091"},{"id":"A137","pred":"mondo_id","subj":"T137","obj":"http://purl.obolibrary.org/obo/MONDO_0100096"},{"id":"A138","pred":"mondo_id","subj":"T138","obj":"http://purl.obolibrary.org/obo/MONDO_0005550"}],"text":"5 Recombinant type I IFN\n\n5.1 Hypothesis: IFNs play a role in anti-viral immunity\nType I IFNs play a primary role in the inhibition of viral replication through the coordination of anti-viral immune responses and modulation of inflammatory responses [24].\n\n5.2 Rational: Recombinant type I IFN can effectively inhibit SARS-CoV2 replication\nIn 24–48 h after infection, SARS-CoV2 replication reaches titer that causes the cytopathic effect in Vero E6 cells, which express ACE2 and thus are susceptible to SARS-CoV2 infection [25]. It is similar to the viral replication kinetics for SARS-CoV [25]. Pretreatment with recombinant type I IFN could effectively inhibit SARS-CoV2 replication at both 24 and 48 h after infection [25]. For SARS-CoV, such an effect was present at 24 h but absent at 48 h after infection [25]. The difference between SARS-CoV2 and SARS-CoV in response to type I IFN treatment may be due to differences in structural proteins of these viruses, including NSP3, ORF3b, and ORF6 [25]."}

{"project":"LitCovid-sample-GO-BP","denotations":[{"id":"T18","span":{"begin":123,"end":154},"obj":"http://purl.obolibrary.org/obo/GO_1903901"},{"id":"T19","span":{"begin":137,"end":154},"obj":"http://purl.obolibrary.org/obo/GO_0019079"},{"id":"T20","span":{"begin":137,"end":154},"obj":"http://purl.obolibrary.org/obo/GO_0019058"},{"id":"T21","span":{"begin":194,"end":210},"obj":"http://purl.obolibrary.org/obo/GO_0006955"},{"id":"T22","span":{"begin":229,"end":251},"obj":"http://purl.obolibrary.org/obo/GO_0006954"},{"id":"T23","span":{"begin":553,"end":570},"obj":"http://purl.obolibrary.org/obo/GO_0019079"},{"id":"T24","span":{"begin":553,"end":570},"obj":"http://purl.obolibrary.org/obo/GO_0019058"},{"id":"T25","span":{"begin":869,"end":891},"obj":"http://purl.obolibrary.org/obo/GO_0034340"}],"text":"5 Recombinant type I IFN\n\n5.1 Hypothesis: IFNs play a role in anti-viral immunity\nType I IFNs play a primary role in the inhibition of viral replication through the coordination of anti-viral immune responses and modulation of inflammatory responses [24].\n\n5.2 Rational: Recombinant type I IFN can effectively inhibit SARS-CoV2 replication\nIn 24–48 h after infection, SARS-CoV2 replication reaches titer that causes the cytopathic effect in Vero E6 cells, which express ACE2 and thus are susceptible to SARS-CoV2 infection [25]. It is similar to the viral replication kinetics for SARS-CoV [25]. Pretreatment with recombinant type I IFN could effectively inhibit SARS-CoV2 replication at both 24 and 48 h after infection [25]. For SARS-CoV, such an effect was present at 24 h but absent at 48 h after infection [25]. The difference between SARS-CoV2 and SARS-CoV in response to type I IFN treatment may be due to differences in structural proteins of these viruses, including NSP3, ORF3b, and ORF6 [25]."}

{"project":"LitCovid-PD-GO-BP","denotations":[{"id":"T18","span":{"begin":123,"end":154},"obj":"http://purl.obolibrary.org/obo/GO_1903901"},{"id":"T19","span":{"begin":137,"end":154},"obj":"http://purl.obolibrary.org/obo/GO_0019079"},{"id":"T20","span":{"begin":137,"end":154},"obj":"http://purl.obolibrary.org/obo/GO_0019058"},{"id":"T21","span":{"begin":194,"end":210},"obj":"http://purl.obolibrary.org/obo/GO_0006955"},{"id":"T22","span":{"begin":229,"end":251},"obj":"http://purl.obolibrary.org/obo/GO_0006954"},{"id":"T23","span":{"begin":553,"end":570},"obj":"http://purl.obolibrary.org/obo/GO_0019079"},{"id":"T24","span":{"begin":553,"end":570},"obj":"http://purl.obolibrary.org/obo/GO_0019058"},{"id":"T25","span":{"begin":869,"end":891},"obj":"http://purl.obolibrary.org/obo/GO_0034340"}],"text":"5 Recombinant type I IFN\n\n5.1 Hypothesis: IFNs play a role in anti-viral immunity\nType I IFNs play a primary role in the inhibition of viral replication through the coordination of anti-viral immune responses and modulation of inflammatory responses [24].\n\n5.2 Rational: Recombinant type I IFN can effectively inhibit SARS-CoV2 replication\nIn 24–48 h after infection, SARS-CoV2 replication reaches titer that causes the cytopathic effect in Vero E6 cells, which express ACE2 and thus are susceptible to SARS-CoV2 infection [25]. It is similar to the viral replication kinetics for SARS-CoV [25]. Pretreatment with recombinant type I IFN could effectively inhibit SARS-CoV2 replication at both 24 and 48 h after infection [25]. For SARS-CoV, such an effect was present at 24 h but absent at 48 h after infection [25]. The difference between SARS-CoV2 and SARS-CoV in response to type I IFN treatment may be due to differences in structural proteins of these viruses, including NSP3, ORF3b, and ORF6 [25]."}

{"project":"LitCovid-sentences","denotations":[{"id":"T154","span":{"begin":0,"end":25},"obj":"Sentence"},{"id":"T155","span":{"begin":27,"end":83},"obj":"Sentence"},{"id":"T156","span":{"begin":84,"end":257},"obj":"Sentence"},{"id":"T157","span":{"begin":259,"end":273},"obj":"Sentence"},{"id":"T158","span":{"begin":274,"end":342},"obj":"Sentence"},{"id":"T159","span":{"begin":343,"end":531},"obj":"Sentence"},{"id":"T160","span":{"begin":532,"end":598},"obj":"Sentence"},{"id":"T161","span":{"begin":599,"end":729},"obj":"Sentence"},{"id":"T162","span":{"begin":730,"end":819},"obj":"Sentence"},{"id":"T163","span":{"begin":820,"end":1006},"obj":"Sentence"}],"namespaces":[{"prefix":"_base","uri":"http://pubannotation.org/ontology/tao.owl#"}],"text":"5 Recombinant type I IFN\n\n5.1 Hypothesis: IFNs play a role in anti-viral immunity\nType I IFNs play a primary role in the inhibition of viral replication through the coordination of anti-viral immune responses and modulation of inflammatory responses [24].\n\n5.2 Rational: Recombinant type I IFN can effectively inhibit SARS-CoV2 replication\nIn 24–48 h after infection, SARS-CoV2 replication reaches titer that causes the cytopathic effect in Vero E6 cells, which express ACE2 and thus are susceptible to SARS-CoV2 infection [25]. It is similar to the viral replication kinetics for SARS-CoV [25]. Pretreatment with recombinant type I IFN could effectively inhibit SARS-CoV2 replication at both 24 and 48 h after infection [25]. For SARS-CoV, such an effect was present at 24 h but absent at 48 h after infection [25]. The difference between SARS-CoV2 and SARS-CoV in response to type I IFN treatment may be due to differences in structural proteins of these viruses, including NSP3, ORF3b, and ORF6 [25]."}

{"project":"2_test","denotations":[{"id":"32413736-10754318-48112978","span":{"begin":253,"end":255},"obj":"10754318"},{"id":"T95987","span":{"begin":253,"end":255},"obj":"10754318"}],"text":"5 Recombinant type I IFN\n\n5.1 Hypothesis: IFNs play a role in anti-viral immunity\nType I IFNs play a primary role in the inhibition of viral replication through the coordination of anti-viral immune responses and modulation of inflammatory responses [24].\n\n5.2 Rational: Recombinant type I IFN can effectively inhibit SARS-CoV2 replication\nIn 24–48 h after infection, SARS-CoV2 replication reaches titer that causes the cytopathic effect in Vero E6 cells, which express ACE2 and thus are susceptible to SARS-CoV2 infection [25]. It is similar to the viral replication kinetics for SARS-CoV [25]. Pretreatment with recombinant type I IFN could effectively inhibit SARS-CoV2 replication at both 24 and 48 h after infection [25]. For SARS-CoV, such an effect was present at 24 h but absent at 48 h after infection [25]. The difference between SARS-CoV2 and SARS-CoV in response to type I IFN treatment may be due to differences in structural proteins of these viruses, including NSP3, ORF3b, and ORF6 [25]."}